I am a catalyst for my clients' drug development, orchestrating pivotal interactions with influential health authorities and translating their guidance into action. Under my leadership, we obtained a second indication for my client's product. My detailed knowledge of the drug, combined with my problem-solving abilities, is the foundation of a successful product launch.

As the Chief Medical Officer, I held a leadership position in our company's product portfolio, focusing on uterine fibroids, endometriosis, IVF, and premature labor. I played a crucial role in defining our strategic direction, overseeing development, and ensuring flawless execution. I was responsible for the medical oversight of all our company molecules, managing clinical operations, and addressing the important area of pharmacovigilance. My most notable achievement was obtaining the approval of linzagolix for the treatment of uterine fibroids in Europe, under the brand name Yselty.

As the chief medical officer, I held the responsibility of overseeing all medical aspects related to PregLem molecules and effectively managed clinical operations and pharmacovigilance. My notable achievement was securing the European approval for Esmya, ulipristal acetate, an innovative medication designed specifically for the treatment of uterine fibroids.

I played a key role as the clinical and medical lead in overseeing the planning, implementation, and management of the Phase III trial for Galerma's acne therapy combination product, Epiduo. This product contains a unique combination of adapalene and benzoyl peroxide. My responsibilities included designing the study, ensuring regulatory compliance, managing patient recruitment and enrollment, coordinating with study sites, and overseeing data collection and analysis. Through my expertise and guidance, we successfully conducted the trial, generating valuable data to support the safety and efficacy of Epiduo for acne treatment.